- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06839989
Una sperimentazione di immunogenicità e sicurezza di MVA-BN negli adulti che vivono con l'HIV per la prevenzione dell'infezione da Mpox, a Kinshasa, DRC (Mbote-HIVAX)
Il progetto MPOX Biology, Outcome, Trasmission ed Epidemiology - Immunizzazione dell'HIV e vaccinazione contro lo studio di esposizione MPOX
This is an open-label, phase 2, immunogenicity and safety trial of the MVA-BN vaccine for the prevention of mpox in adults living with HIV with different level of CD4 counts in Kinshasa, DRC.
The study team aims to investigate whether the administration of 2 standard subcutaneous doses of the Modified Vaccinia Ankara of Bavarian Nordic (MVA-BN) vaccine given 28 days apart, is immunogenic and safe when administered to People Living with HIV (PLHIV) with different levels of CD4 counts in the Democratic Republic of the Congo (DRC).
Enrollment will be stratified according to three different subgroups based on CD4 counts assessed during visit 1A: <200 cells/µL; 200 to 499 cells/µL; ≥ 500 cells/µL. A total of 600 participants will be included in the trial, with 200 participants per subgroup.
All participants will be invited to 6 trial visits over a period of 7 months.
This study will take place in cooperation with the National Programme for the Fight against AIDS (PNLS), the 'Programme Elargi de Vaccination (PEV)' and the 'Institut National de Santé Publique (INSP)'. As part of the response to the current mpox epidemic in DRC, a large cohort of about 10,000 individuals living in Kinshasa will be vaccinated in this program. Vaccination will take place in the Centre Hospitalier Kabinda (CHK) and the Pakadjuma Health Centre. All people living with HIV (PLHIV) with the intention to be vaccinated in the CHK, will be asked for their willingness to participate in the MBOTE-HIVAX clinical trial until the sample size of 600 participants needed for this clinical trial is reached.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Kinshasa, Repubblica democratica del Congo
- Centre Hospitalier Kabinda
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years and ≤ 45 years at time of informed consent
- Able and willing to provide written informed consent
- Infected with HIV and receiving combination antiretroviral therapy (ART) for ≥ 8 weeks prior to study entry and vaccination
- Preparedness to follow the study schedule
- Willingness to use contraception for 1 month after each vaccination (only for women of childbearing potential)
Exclusion Criteria:
- A known history of mpox and/or smallpox
- A known history of vaccination with 1st, 2nd or 3rd generation smallpox vaccines, or vaccine platforms that contain MVA as a vector
- Planned MVA-based vaccination (other than study vaccination) during the trial
- Close contact to a confirmed mpox case in the 3 weeks prior to study enrollment
- Uncontrolled severe infection or other condition requiring hospitalization
- Pregnancy
- History of anaphylaxis or severe allergic reaction to any vaccine or known allergy to one of the components of the study vaccine
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: CD4 <200
Participants in this arm are stratified in the group with participants with a CD4 level below 200cells/µL. |
All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28. |
|
Sperimentale: CD4 200-499
Participants in this arm are stratified in the group with participants with a CD4 level between 200 and 499 cells/µL. |
All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28. |
|
Sperimentale: CD4 >= 500
Participants in this arm are stratified in the group with participants with a CD4 level of 500cells/µL or more. |
All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Seroconversion rates for monkeypox virus (MPXV) neutralizing antibodies
Lasso di tempo: 2 weeks after the last vaccine dose
|
Seroconversion two weeks after administration of two standard doses of MVA-BN, defined as either the appearance of an MPXV neutralizing antibody titre (NT50) greater than or equal to the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline |
2 weeks after the last vaccine dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and reactogenicity of the MVA-BN vaccine in PLHIV
Lasso di tempo: Up to day 14 and until end of participation
|
Solicited local AEs (pain, redness, swelling, induration, and itch at the injection site) and systemic AEs (generalized myalgia, headache, fatigue, nausea and/or vomiting, chills and/or fever (≥ 38.0°C)) up to day 14 post vaccination Unsolicited AEs up to day 14 post vaccination SAEs until the end of participation |
Up to day 14 and until end of participation
|
|
Seroconversion rates for vaccinia virus (VACV) neutralizing antibodies
Lasso di tempo: 2 weeks after last vaccine dose
|
Seroconversion two weeks after administration of two standard doses of MVA-BN, defined as either the appearance of an VACV neutralizing antibody titre (NT50) greater than or equal to the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline. |
2 weeks after last vaccine dose
|
|
Waning of MPXV neutralizing antibodies in PLHIV
Lasso di tempo: On day 14 and month 6
|
The ratio between neutralizing antibody titre against MPXV at 6 months (D28 + 6M) versus 14 days (D28 + 14 days) after administration of two standard doses of MVA-BN. |
On day 14 and month 6
|
|
Waning of VACV neutralizing antibodies in PLHIV
Lasso di tempo: On day 14 and month 6
|
The ratio between neutralizing antibody titre against VACV at 6 months (D28 + 6M) versus 14 days (D28 + 14 days) after administration of two standard doses of MVA-BN. |
On day 14 and month 6
|
|
Seroconversion rates and IgG antibody titre dynamics against MPXV and VACV antigens in serum
Lasso di tempo: day 0 (prior to first dose), Day14, Day 28, Day 28+14 days, Day 28+6Months
|
The absolute IgG antibody titre against the following antigens: A35R, H3L, B2R, A5L, A27L, B6R, E8L and A29L from mpox, and A33R and B5 from vaccinia virus at D14, D28 (second dose), D28+14d, D28+6M after administration of two standard doses of MVA-BN, be defined as either the appearance of Median Fluorescent Values (MFI) greater than the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline. |
day 0 (prior to first dose), Day14, Day 28, Day 28+14 days, Day 28+6Months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Laurens Liesenborghs, MD, Institute of Tropical Medicine
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Mbote-HIVAX
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .